CardioTech's CardioPass
This article was originally published in The Gray Sheet
Executive Summary
IDE submission is planned for late 2001 to conduct clinical trials on the synthetic coronary artery bypass graft. The trials could take place at ten to 20 centers, enrolling 200 patients, according to CardioTech. Intended for no-option heart disease patients who already have undergone saphenous vein graft procedures, the market for CardioPass is estimated at $1.5 bil. based on a price of $1,500 per graft